<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Recently, the Nateglinide and <z:chebi fb="0" ids="9927">Valsartan</z:chebi> in <z:hpo ids='HP_0000833'>Impaired Glucose Tolerance</z:hpo> Outcomes Research Trial demonstrated that treatment with the angiotensin receptor blocker (ARB) <z:chebi fb="0" ids="9927">valsartan</z:chebi> for 5 years resulted in a relative reduction of 14% in the incidence of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in subjects with impaired <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism (IGM) </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated whether improvements in β-cell function and/or insulin sensitivity underlie these preventive effects of the ARB <z:chebi fb="0" ids="9927">valsartan</z:chebi> in the <z:hpo ids='HP_0003674'>onset</z:hpo> of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: In this randomized controlled, double-blind, two-center study, the effects of 26 weeks of <z:chebi fb="0" ids="9927">valsartan</z:chebi> (320 mg daily; n = 40) or placebo (n = 39) on β-cell function and insulin sensitivity were assessed in subjects with impaired fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> and/or <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo>, using a combined hyperinsulinemic-euglycemic and hyperglycemic clamp with subsequent arginine stimulation and a 2-h 75-g oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test (OGTT) </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment effects were analyzed using ANCOVA, adjusting for center, glucometabolic status, and sex </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:chebi fb="0" ids="9927">Valsartan</z:chebi> increased first-phase (P = 0.028) and second-phase (P = 0.002) <z:chebi fb="105" ids="17234">glucose</z:chebi>-stimulated insulin secretion compared with placebo, whereas the enhanced arginine-stimulated insulin secretion was comparable between groups (P = 0.25) </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, <z:chebi fb="0" ids="9927">valsartan</z:chebi> increased the OGTT-derived insulinogenic index (representing first-phase insulin secretion after an oral <z:chebi fb="105" ids="17234">glucose</z:chebi> load; P = 0.027) </plain></SENT>
<SENT sid="6" pm="."><plain>Clamp-derived insulin sensitivity was significantly increased with <z:chebi fb="0" ids="9927">valsartan</z:chebi> compared with placebo (P = 0.049) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="9927">Valsartan</z:chebi> treatment significantly decreased systolic and diastolic blood pressure compared with placebo (P &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>BMI remained unchanged in both treatment groups (P = 0.89) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Twenty-six weeks of <z:chebi fb="0" ids="9927">valsartan</z:chebi> treatment increased <z:chebi fb="105" ids="17234">glucose</z:chebi>-stimulated insulin release and insulin sensitivity in normotensive subjects with IGM </plain></SENT>
<SENT sid="10" pm="."><plain>These findings may partly explain the beneficial effects of <z:chebi fb="0" ids="9927">valsartan</z:chebi> in the reduced incidence of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>